<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03572049</url>
  </required_header>
  <id_info>
    <org_study_id>MSG15</org_study_id>
    <secondary_id>MSG-15</secondary_id>
    <secondary_id>UTN U1111-1228-5154</secondary_id>
    <nct_id>NCT03572049</nct_id>
  </id_info>
  <brief_title>Endemic Mycoses Treatment With SUBA-itraconazole vs Itraconazole</brief_title>
  <acronym>MSG15</acronym>
  <official_title>SUBA-itraconazole Versus Conventional Itraconazole in the Treatment of Endemic Mycoses: a Multi-center, Open-label Comparative Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multi-center, randomized, open-label parallel arm study involving&#xD;
      patients with proven or probable invasive endemic fungal infection to ascertain the&#xD;
      pharmacokinetics, safety, efficacy, tolerability and health economics of oral&#xD;
      SUBA-itraconazole compared to conventional itraconazole. Patients will receive randomized&#xD;
      open-label study drug (SUBA-itraconazole or conventional itraconazole) over a 42 day period&#xD;
      and then continue therapy until Day 180. Patients will be stratified based on clinically&#xD;
      reported infection with the human immunodeficiency virus (HIV).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multi-center, randomized, open-label parallel arm study involving&#xD;
      patients with proven or probable invasive endemic fungal infection to ascertain the&#xD;
      pharmacokinetics, safety, efficacy, and tolerability of oral SUBA-itraconazole or&#xD;
      itraconazole. Patients will receive randomized open-label study drug (either SUBA-&#xD;
      itraconazole 130 mg twice daily or itraconazole 200 mg twice daily) over a 42-day period and&#xD;
      then continue on their assigned open-label therapy until day 180.&#xD;
&#xD;
      The study sample size will be 80 evaluable patients - target enrollment (three arms:&#xD;
      approximately 40 histoplasmosis, 20 coccidioidomycosis, 20 other endemic fungal infections).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 17, 2018</start_date>
  <completion_date type="Anticipated">October 31, 2021</completion_date>
  <primary_completion_date type="Actual">May 31, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of Plasma Itraconazole Levels and Hydroxyitraconazole levels at Day 14</measure>
    <time_frame>Baseline to Day 14</time_frame>
    <description>Time to achieve therapeutic itraconazole and hydroxyitraconazole levels by evaluating Inter-patient variability as calculated by co-efficient of variation on plasma specimens collected on Day 14</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adherence to study medication regimens Days 1-42</measure>
    <time_frame>Baseline to Day 42</time_frame>
    <description>The percentage of prescribed capsules returned in capsule count on Day 42</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of treatment related adverse events Days 1-42</measure>
    <time_frame>Baseline to Day 42</time_frame>
    <description>Comparison of the number of treatment related adverse events in each arm occurring Days 1-42.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of Plasma Itraconazole Levels and Hydroxyitraconazole levels at Day 42</measure>
    <time_frame>Baseline to day 42</time_frame>
    <description>Percentage of patients with therapeutic itraconazole and hydroxyitraconazole levels as measured in plasma trough levels Day 42</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resolution of signs and symptoms of invasive fungal infection on Day 42</measure>
    <time_frame>Baseline to day 42</time_frame>
    <description>We will measure specific signs and symptoms related to endemic fungal infection, comparing baseline findings to Day 42 findings using physical examination and patient history.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of days of Hospitalization at Day 180</measure>
    <time_frame>Baseline to day 180</time_frame>
    <description>The number of days of Hospitalization occurring between Day 1-180</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Invasive Fungal Infections</condition>
  <arm_group>
    <arm_group_label>SUBA itraconazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stage 1: Day 1-3 two 65 mg capsules three times daily with food. Days 4-42 two 65 mg capsules twice daily with food.&#xD;
Stage 2 : Days 43-180 two 65 mg capsules twice daily with food</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional itraconazole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Stage 1: Day 1-3 two 100 mg capsules three times daily with food. Days 4-42 two 100 mg capsules twice daily with food.&#xD;
Stage 2 : Days 43-180 two 100 mg capsules twice daily with food</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SUBA itraconazole</intervention_name>
    <description>SUBA itraconazole study drug will consist of two 65 mg capsules to be taken three times a day with food for days 1-3 of study. For days 4-180 of study, two 65mg capsules will be taken twice daily with food.</description>
    <arm_group_label>SUBA itraconazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Conventional itraconazole</intervention_name>
    <description>Conventional itraconazole comparator drug will consist of two 100 mg capsules to be taken three times a day with food for days 1-3 of study. For days 4-180 of study, two 100 mg capsules will be taken twice daily with food.</description>
    <arm_group_label>Conventional itraconazole</arm_group_label>
    <other_name>itraconazole</other_name>
    <other_name>Sporanox</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male and female patients age &gt; 18 years who have given written informed consent to&#xD;
             participate&#xD;
&#xD;
          2. Patients with a proven or probable endemic mycosis (Histoplasma, Coccidioides,&#xD;
             Paracoccidioides, Blastomyces, Sporothrix, Talaromyces marneffei (formerly Penicillium&#xD;
             marneffei) according to current EORTC/MSG (Mycoses Study Group) criteria, including&#xD;
             patients who:&#xD;
&#xD;
               -  Are immunosuppressed, including as a result of HIV/AIDS&#xD;
&#xD;
               -  Have had a heart, lung or bone marrow transplant&#xD;
&#xD;
               -  Have had chemotherapy for cancer&#xD;
&#xD;
               -  Are otherwise normal hosts&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Significant liver dysfunction as evidenced by at least 5 times greater than upper&#xD;
             limits of normal baseline ALT (alanine aminotransferase) , AST (aspartate&#xD;
             aminotransferase), alkaline phosphatase, or total bilirubin.&#xD;
&#xD;
          2. Use of an alternative antifungal therapy (IV or oral) for more than 14 days for this&#xD;
             infection, with the exception of Coccidioidomycosis. Subjects with Coccidioidomycosis&#xD;
             who previously received fluconazole therapy for more than 14 days may be included, if&#xD;
             in the opinion of the investigator, they are having an inadequate response or, are&#xD;
             intolerant of fluconazole (e.g. due to adverse events). Such subjects must washout&#xD;
             from fluconazole for 7 days (~5 half-lives of fluconazole) before starting&#xD;
             investigational therapy.&#xD;
&#xD;
          3. Evidence of CNS (central nervous system) infection.&#xD;
&#xD;
          4. Unable to take PO medications.&#xD;
&#xD;
          5. Female patients who are lactating or pregnant.&#xD;
&#xD;
             Women should be:&#xD;
&#xD;
               1. Postmenopausal for 1 year,&#xD;
&#xD;
               2. Post-hysterectomy or bilateral oophorectomy,&#xD;
&#xD;
               3. If of child bearing potential have a negative Î²-HCG (human chorionic&#xD;
                  gonadotropin) at screening and using highly effective method of birth control&#xD;
                  throughout course of study or remain abstinent for duration of study.&#xD;
&#xD;
          6. Documented intolerance, allergy or hypersensitivity to an azole.&#xD;
&#xD;
          7. Inability to comply with study treatment, study visits, and study procedures.&#xD;
&#xD;
          8. Known history of congestive cardiac failure on medical treatment, fungal endocarditis,&#xD;
             or other causes of ventricular dysfunction that may outweigh the benefit of&#xD;
             itraconazole.&#xD;
&#xD;
          9. Patients with active TB (tuberculosis)&#xD;
&#xD;
         10. Concurrent use of astemizole, rifampin/rifampicin, rifabutin, ergot alkaloids, long&#xD;
             acting barbiturates, carbamazepine, pimozide, quinidine, neostigmine, terfenadine,&#xD;
             ketoconazole, valproic acid, or St. John's wort in the 5 days prior to first&#xD;
             administration of study drug.&#xD;
&#xD;
         11. Any known or suspected condition of the patient that may jeopardize adherence to the&#xD;
             protocol requirements or impede the accurate measurement of efficacy.&#xD;
&#xD;
         12. Treatment with any investigational agent in the 30 days prior to study entry.&#xD;
&#xD;
         13. Patients unlikely to survive 30 days (including severe fungal disease defined by&#xD;
             systolic blood pressure (SBP) &lt; 90; hypoxia &lt; 60).&#xD;
&#xD;
         14. Patients with body weight &lt; 40 kg.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter G Pappas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_official>
    <last_name>George R Thompson, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of California, Davis</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrej Spec, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Arizona</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California at Davis</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metro Infectious Disease Associates</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unniversity of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University in St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710-1000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Santo TomÃ¡s</name>
      <address>
        <city>Panama</city>
        <country>Panama</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Panama</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 1, 2018</study_first_submitted>
  <study_first_submitted_qc>June 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2018</study_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Peter Pappas</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Histoplasmosis</keyword>
  <keyword>Coccidioidomycosis</keyword>
  <keyword>Blastomycosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Invasive Fungal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Itraconazole</mesh_term>
    <mesh_term>Hydroxyitraconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

